Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society
| Autor: | Norhayati Omar, Nurhayati Mohd Marzuki, Lye Mun Tho, Pathmanathan Rajadurai, Yong Kek Pang, Phaik-Leng Cheah, Soon Hin How, Noriah Othman, Muhammad Azrif Ahmad Annuar, Chong-Kin Liam, Ros Suzanna Ahmad Bustamam |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
0301 basic medicine Pulmonary and Respiratory Medicine Cancer Research medicine.medical_specialty Lung Neoplasms Statement (logic) Biopsy First line medicine.medical_treatment Targeted therapy 03 medical and health sciences 0302 clinical medicine First line therapy Carcinoma Non-Small-Cell Lung Biomarkers Tumor Humans Medicine Genetic Predisposition to Disease Medical physics Lung cancer Neoplasm Staging business.industry Disease progression Malaysia High-Throughput Nucleotide Sequencing medicine.disease 030104 developmental biology Molecular Diagnostic Techniques Oncology 030220 oncology & carcinogenesis Treatment strategy Female Non small cell business Genome-Wide Association Study |
| Zdroj: | Lung Cancer. 136:65-73 |
| ISSN: | 0169-5002 |
| DOI: | 10.1016/j.lungcan.2019.08.005 |
| Popis: | In the recent years, increased understanding of the molecular profiles of non-small cell lung cancer (NSCLC) has allowed for targeted treatment of actionable genetic mutations. The management of NSCLC now requires multiple molecular tests to guide the treatment strategy. In the light of this, there is a need to establish a molecular testing consensus statement for advanced NSCLC patients in Malaysia. This Malaysian consensus statement was developed by a panel of experts, chaired by a pathologist and composed of three other pathologists, four respiratory physicians and three oncologists. It reflects currently available scientific data and adaptations of recommendations from international guidelines to the local landscape. Expert recommendations on different aspects of molecular testing agreed upon by the panel are provided as structured discussions. These recommendations address the appropriate patients and samples to be tested, as well as when and how these tests should be performed. The algorithms for molecular testing in metastatic NSCLC, in the first line setting and upon disease progression beyond first line therapy, were developed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect